Stifel Financial’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.83M | Buy |
13,877
+2,472
| +22% | +$328K | ﹤0.01% | 2031 |
|
|
2025
Q4 | $1.62M | Sell |
11,405
-2,592
| -19% | -$376K | ﹤0.01% | 2085 |
|
|
2025
Q3 | $1.96M | Sell |
13,997
-2,918
| -17% | -$395K | ﹤0.01% | 1933 |
|
|
2025
Q2 | $2.13M | Sell |
16,915
-1,281
| -7% | -$147K | ﹤0.01% | 1807 |
|
|
2025
Q1 | $2.01M | Sell |
18,196
-4,480
| -20% | -$568K | ﹤0.01% | 1752 |
|
|
2024
Q4 | $3.1M | Buy |
22,676
+4,425
| +24% | +$547K | ﹤0.01% | 1498 |
|
|
2024
Q3 | $2.1M | Buy |
18,251
+84
| +0.5% | +$11.5K | ﹤0.01% | 1734 |
|
|
2024
Q2 | $2.5M | Sell |
18,167
-951
| -5% | -$130K | ﹤0.01% | 1570 |
|
|
2024
Q1 | $2.64M | Buy |
19,118
+749
| +4% | +$102K | ﹤0.01% | 1526 |
|
|
2023
Q4 | $2.42M | Sell |
18,369
-425
| -2% | -$48.9K | ﹤0.01% | 1540 |
|
|
2023
Q3 | $2.11M | Buy |
18,794
+3,802
| +25% | +$400K | ﹤0.01% | 1558 |
|
|
2023
Q2 | $1.41M | Sell |
14,992
-587
| -4% | -$57.4K | ﹤0.01% | 1852 |
|
|
2023
Q1 | $1.58M | Sell |
15,579
-142
| -0.9% | -$14.8K | ﹤0.01% | 1732 |
|
|
2022
Q4 | $1.88M | Sell |
15,721
-1,746
| -10% | -$205K | ﹤0.01% | 1566 |
|
|
2022
Q3 | $1.86M | Sell |
17,467
-1,503
| -8% | -$153K | ﹤0.01% | 1536 |
|
|
2022
Q2 | $1.85M | Sell |
18,970
-5,259
| -22% | -$485K | ﹤0.01% | 1550 |
|
|
2022
Q1 | $2.27M | Sell |
24,229
-2,326
| -9% | -$197K | ﹤0.01% | 1528 |
|
|
2021
Q4 | $2.26M | Sell |
26,555
-6,619
| -20% | -$609K | ﹤0.01% | 1522 |
|
|
2021
Q3 | $3.18M | Sell |
33,174
-2,843
| -8% | -$269K | ﹤0.01% | 1278 |
|
|
2021
Q2 | $3.5M | Buy |
36,017
+4,156
| +13% | +$398K | 0.01% | 1226 |
|
|
2021
Q1 | $3.1M | Buy |
31,861
+896
| +3% | +$94K | 0.01% | 1238 |
|
|
2020
Q4 | $2.97M | Buy |
30,965
+2,564
| +9% | +$248K | 0.01% | 1147 |
|
|
2020
Q3 | $2.73M | Buy |
28,401
+5,104
| +22% | +$590K | 0.01% | 1065 |
|
|
2020
Q2 | $2.84M | Buy |
23,297
+3,610
| +18% | +$399K | 0.01% | 975 |
|
|
2020
Q1 | $1.72M | Sell |
19,687
-2,914
| -13% | -$285K | ﹤0.01% | 1120 |
|
|
2019
Q4 | $2.43M | Buy |
22,601
+7,260
| +47% | +$760K | 0.01% | 1213 |
|
|
2019
Q3 | $1.4M | Buy |
15,341
+7,793
| +103% | +$728K | ﹤0.01% | 1544 |
|
|
2019
Q2 | $643K | Buy |
7,548
+3,715
| +97% | +$305K | ﹤0.01% | 2068 |
|
|
2019
Q1 | $344K | Buy |
+3,833
| New | +$320K | ﹤0.01% | 2280 |
|
|
2018
Q4 | – | Sell |
-3,102
| Closed | -$383K | – | 2764 |
|
|
2018
Q3 | $383K | Buy |
+3,102
| New | +$352K | ﹤0.01% | 2223 |
|
|
2017
Q4 | – | Sell |
-4,029
| Closed | -$246K | – | 2703 |
|
|
2017
Q3 | $246K | Buy |
+4,029
| New | +$213K | ﹤0.01% | 2259 |
|
|
2016
Q1 | – | Sell |
-4,104
| Closed | -$232K | – | 2334 |
|
|
2015
Q4 | $232K | Buy |
+4,104
| New | +$209K | ﹤0.01% | 2046 |
|
Other funds holding NBIX
VPM
VCM
Stifel Financial's NBIX Position: Q1 2026 in Review
Stifel Financial increased its Neurocrine Biosciences (NBIX) stake by 22% in Q1 2026, buying an estimated $328K and bringing the position to 13,877 shares worth $1.83M. The position accounts for ﹤0.01% of the portfolio, ranked #2031.
Stifel Financial first reported a position in NBIX in Q4 2015 and has held it in 32 quarters since. The position peaked at $3.5M in Q2 2021. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Stifel Financial held 13,877 shares of Neurocrine Biosciences worth $1.83M as of Q1 2026.
- Stifel Financial bought 2,472 Neurocrine Biosciences shares in Q1 2026, an estimated $328K.
- Neurocrine Biosciences made up ﹤0.01% of Stifel Financial's portfolio in Q1 2026, its #2031 holding.
- Stifel Financial first reported a position in Neurocrine Biosciences in Q4 2015 and has held it in 32 quarters since.
- Stifel Financial's Neurocrine Biosciences position peaked at $3.5M in Q2 2021.
- 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Stifel Financial's 13F filing for Q1 2026, filed 12 May 2026.